These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16847824)

  • 21. Issues in the use of adaptive clinical trial designs.
    Emerson SS
    Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for including patients recruited during interim analysis of clinical trials.
    Faldum A; Hommel G
    J Biopharm Stat; 2007; 17(6):1211-25. PubMed ID: 18027227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standard versus adaptive monitoring procedures: A commentary.
    Fleming TR
    Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symmetric group sequential test designs.
    Emerson SS; Fleming TR
    Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Information-based monitoring of clinical trials.
    Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3236-44; discussion 3320-5, 3326-47. PubMed ID: 16927248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size for two-stage studies with maintenance therapy.
    Feng W; Wahed AS
    Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive increase in sample size when interim results are promising: a practical guide with examples.
    Mehta CR; Pocock SJ
    Stat Med; 2011 Dec; 30(28):3267-84. PubMed ID: 22105690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
    Cheng B; Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.
    Ellenberg SS
    Oncology (Williston Park); 1989 Aug; 3(8):39-46; discussion 48, 51. PubMed ID: 2519197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress versus precision: challenges in clinical trial design for left ventricular assist devices.
    Parides MK; Moskowitz AJ; Ascheim DD; Rose EA; Gelijns AC
    Ann Thorac Surg; 2006 Sep; 82(3):1140-6. PubMed ID: 16928569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of a mis-specification of the response rate under standard treatment in sequential clinical trials.
    Sébille V; Bellissant E
    Fundam Clin Pharmacol; 2005 Oct; 19(5):569-78. PubMed ID: 16176336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A method to estimate the variance of an endpoint from an on-going blinded trial.
    Xing B; Ganju J
    Stat Med; 2005 Jun; 24(12):1807-14. PubMed ID: 15803440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.